

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

35. (Currently amended) A method of treating non-small cell lung cancer NSCLC in a subject comprising administering to said subject an effective amount of the double-stranded molecule of composition according to claim 44 or the composition of claim 60, thereby treating non-small cell lung cancer NSCLC in said subject.

36-43. (Canceled).

44. (Previously presented) A double-stranded molecule comprising a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIF11 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing a KIF11 gene, inhibits expression of said gene, wherein said KIF11 target sequence consists of SEQ ID NO: 34.

45-47. (Canceled).

48. (Original) The double-stranded molecule of claim 44, wherein said double-stranded molecule is a single ribonucleotide transcript comprising the sense strand and the antisense strand linked via a single-stranded ribonucleotide sequence.

49-53. (Canceled).

54. (Previously presented) A vector encoding the double-stranded molecule of claim 44 or 48.

55. (Original) The vector of claim 54, wherein the vector encodes a transcript having a secondary structure and comprises the sense strand and the antisense strand.

56. (Original) The vector of claim 55, wherein the transcript further comprises a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand.

57- 59. (Canceled).

60. (Previously presented) A composition for treating non small cell lung cancer (NSCLC), said composition comprising a pharmaceutically effective amount of an siRNA against KIF11, wherein the siRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIF11 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said siRNA, and wherein said siRNA, when introduced into a cell expressing a KIF11 gene, inhibits expression of said gene, wherein said KIF11 target sequence consists of SEQ ID NO:34.

61- 69. (Canceled).